Somatostatin Analogs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2028
Global Somatostatin Analogs Market: Overview
The somatostatin analogs market has evolved steadily from the commercial synthesis of hundreds of analogues with more selective and prolonged action in antitumor activity. Somatostatin analogs block the hormones produced by their tumor and hence show clinical therapeutic effect in the treatment of a range of diseases caused by numerous tumors. Clinicians have been harnessing potential of these analogs in treating range of diseases caused by endocrine pancreatic tumors, ectopic tumors, vasoactive intestinal peptide (VIP)-producing tumors, and growth hormone secreting adenoma. A few randomized trials have also established their efficacy in slowing down the progression of various diseases.
Two of the key long-term acting products in the somatostatin analogs market are octreotide and lanreotide. Most prominently and recently, researchers have using the synthetic analogs for managing neuroendocrine tumors, where they utilize the analogs for their anti-angiogenic, apoptotic, and anti-proliferative properties.
Global Somatostatin Analogs Market: Growth Dynamics
Clinical avenues for the application of somatostatin analogs are expanding, with researchers able to prolong the activity and therapeutic efficacy of the analogs. The potential of the somatostatin analogs market has no doubt expanded on the back the growing body of research. Over the past 10 years, these analogs have emerged out as especially promising for the treatment of rare tumors. A case in point is gastroenteropancreatic neuroendocrine tumors. GEP NETs are hard to diagnose and harder to treat. Particularly, the somatostatin analogs market has seen a new application avenue in somatostatin analogue-based imaging methods.
Growing research in endocrine pharmacology has helped the healthcare industry understand the antitumor activity of these analogs, and has underpinned the evolution of the somatostatin analogs market. Advancement in the molecular biology of polymerase chain reaction and growing understanding of immunohistochemistry of rare tumors have engendered sizable investments in the somatostatin analogs market. Growing adoption of drugs based on long-acting somatostatin analogues is boosting the prospects for pharmaceuticals in the somatostatin analogs market. Growing investments in developed economies for the treatment of novel drug therapies are bolstering the prospects. Further, government healthcare organizations in developed regions have also made policies for subsidizing the treatment for rare diseases.
Global Somatostatin Analogs Market: Notable Developments
Taking somatostatin analogs at higher doses may be harmful, but may be the only option for some rare diseases. Recent clinical trials in Europe has flagged this for the treatment of GEP NETs. This might pave way for a lucrative avenue for pharmaceuticals in the somatostatin analogs market.
Researchers at a multicenter study tried to find whether somatostatin analogs administered at higher dosage than the conventional for patients with metastatic NETs had beneficial effects on disease progression. The study was retrospective in nature. The study looked at all clinical data in 13 Italian centers from 2004 to 2017. Each individual in the cohort of 140 patients had either gastrointestinal NET or pancreatic NET. The histological classification was based on the WHO guidelines.
The researchers concluded that using high-dose of commercially available somatostatin analogs as second-line of therapy improved progression-free survival. Delaying the treatment could lead to tumor progression or even death, concluded the investigators. Such studies have helped to understand the biochemical effects of analogues better, thus opening new clinical avenues for the commercialization in the somatostatin analogs market.
Some of the key players operating in the somatostatin analogs market are
Global Somatostatin Analogs Market: Regional Assessment
The somatostatin analogs market is seeing substantial prospects in the regions of Latin America, Asia Pacific, the Middle East and Africa, Europe, and North America. Of these, the avenues are incredibly attractive in North America and Europe. North America especially the U.S. has seen a wide array of clinical studies to understand and improve the therapeutic potential of somatostatin analogs in antitumor activity. Europe is witnessing surge in investments in novel drug therapies for hormonal-imbalance diseases. Further, Asia Pacific is likely to emerge as a promising region for pharmaceuticals in the global somatostatin analogs market.
The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach. The researchers compile the necessary information that enlightens the CXOs about the current growth opportunities in a specific market and enables them to make the most of the opportunities.
TMR Research is a leader in developing well-researched reports. The expertise of the researchers at TMR Research makes the report stand out from others. TMR Research reports help the stakeholders and CXOs make impactful decisions through a unique blend of innovation and analytical thinking. The use of innovation and analytical thinking while structuring a report assures complete and ideal information of the current status of the market to the stakeholders.
TMR Research has rich experience in developing state-of-the-art reports for a wide array of markets and sectors. The brilliance of the experts at TMR Research and their alacrity to conduct thorough research and create phenomenal reports makes TMR Research better than others.
5-Point Growth Formula
The 5-point growth formula developed by TMR Research provides an insight to the stakeholders and CXOs about the current situation in the market. The growth formula makes the report a perfect companion for the stakeholders and CXOs.
The 5-point growth formula includes the following points:
Current and Future Threats
Along with studying the opportunities necessary for growth, threats are also an important aspect to look upon for the companies and stakeholders in a specific sector. TMR Research studies every negative aspect that will hinder the growth of a specific area of business and includes it in the report. The stakeholders and CXOs will have the benefit of assessing the threat and take the necessary steps to prevent the hindrance caused due to the threats.
Accurate Trend Analysis
Keeping up with the latest trends is crucial in any business or sector. While stakeholders are aware of the trends that are on the surface, TMR Researchers find trends that are deeply entrenched in the particular market or sector. The reports are constantly updated with the latest trends so that the stakeholders and CXOs can derive benefits from the trends and generate good revenues.
Demography forms an important part of the growth pattern of all the markets. Diving deep into the demographics enables maximum output from specific areas. The TMR Research team assesses every region and picks out the vital points that have a large impact on the growth of a market.
The analysts at TMR Research conduct an all-round analysis on the competitive landscape of the market. The observations recorded by the analysts are added to the reports so that every stakeholder gets a glimpse of the competitive scenario and frame their business plans according to the situation.
The COVID-19 outbreak has changed the growth projections of numerous sectors and businesses. The analysts at TMR Research have conducted a conscientious survey on the markets after the pandemic struck. The analysts have put forth their brilliant and well-researched opinions in the report. The opinions will help the stakeholders to plan their strategy accordingly.
The reports offer answers to the top 7 questions that revolve around the growth of the market
Flat 10% discount on Single User License if you prebook this report
Flat 10% discount on Multiple User License if you prebook this report
Flat 10% discount on Corporate License if you prebook this report